Sarepta Therapeutics, Inc. (SRPT)
Market Cap | 12.22B |
Revenue (ttm) | 1.24B |
Net Income (ttm) | -535.98M |
Shares Out | 93.86M |
EPS (ttm) | -5.80 |
PE Ratio | n/a |
Forward PE | 63.27 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 54,915 |
Open | 131.16 |
Previous Close | 130.23 |
Day's Range | 128.61 - 131.16 |
52-Week Range | 55.25 - 159.89 |
Beta | 0.93 |
Analysts | Strong Buy |
Price Target | 161.61 (+24.87%) |
Earnings Date | Apr 30, 2024 |
About SRPT
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping... [Read more]
Financial Performance
In 2023, SRPT's revenue was $1.24 billion, an increase of 33.26% compared to the previous year's $933.01 million. Losses were -$535.98 million, -23.81% less than in 2022.
Financial StatementsAnalyst Forecast
According to 18 analysts, the average rating for SRPT stock is "Strong Buy." The 12-month stock price forecast is $161.61, which is an increase of 24.87% from the latest price.
News
Sarepta Therapeutics to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in fire...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on Feb. 29, 2024 that were previously app...
Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the official opening of Route 79, The Duchenne ...
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the fourth quarter and ful...
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2023 financial results...
U.S. FDA to not conduct advisers' meet for Sarepta's Duchenne gene therapy
Sarepta Therapeutics said on Friday that the U.S. FDA will not conduct a meeting of its advisers and will do a priority review for traditional approval of its gene therapy Elevidys for a muscle wastin...
Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication
CAMBRIDGE, Mass.--(BUSINESS WIRE)--The U.S. FDA accepted and filed an efficacy supplement to expand the ELEVIDYS indication.
Sarepta says its experimental Duchenne drug more effective than older medicine
Sarepta Therapeutics said on Monday a mid-stage trial showed its experimental drug produced higher levels of a specific protein deficient in some patients with Duchenne muscular dystrophy (DMD), a mus...
Sarepta Therapeutics Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta announces positive data from Part B of MOMENTUM, a Phase 2 study of SRP-5051 in patients with Duchenne amenable to skipping exon 51.
Sarepta Therapeutics Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that screening is underway in Study SRP-9003-30...
Sarepta Rebounded. Its Gene Therapy Is Back on Course.
The future of Sarepta Therapeutics' gene therapy for Duchenne muscular dystrophy looked grim two months ago. There's been a 180 since.
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2023 Net Product Revenue
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported preliminary* fourth quarter and full-year 2023 n...
Dyne Therapeutics stock gains, Sarepta falls after muscular dystrophy trial results
Dyne Therapeutics Inc. shares DYN, -1.80% jumped 40% premarket on Wednesday after the company released new data from trials of two investigational treatments for genetic muscle disorders. The experime...
Sarepta Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the 42nd...
Sarepta Therapeutics Submits Efficacy Supplement to Expand the ELEVIDYS Label to include Duchenne Muscular Dystrophy Patients without Restriction to Age or Ambulatory Status
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta submits efficacy supplement to expand ELEVIDYS label to include Duchenne patients without restriction to age or ambulatory status.
Insider Buys: Lumen, Air Products, Inari, Remitly and Sarepta
Hosted by Brian Sullivan, “Last Call” is a fast-paced, entertaining business show that explores the intersection of money, culture and policy. Tune in Monday through Friday at 7 p.m.
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT
NEW YORK , Nov. 4, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues investigating potential securities claims on behalf of shareholders of Sarepta Therapeutics, ...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
NEW YORK , Nov. 3, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT). Such investors are advis...
Sarepta Therapeutics to Present at the UBS Biopharma Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fi...
Sarepta Therapeutics Announces Third Quarter 2023 Financial Results and Recent Corporate Developments
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter 2023. “T...
ROSEN, A LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPT
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, continues investigating potential securities claims on behalf of shareholders of Sarepta Therapeutics, Inc. (NASDAQ: ...
Sarepta shares slump as muscle disorder therapy fails to meet key trial goal
Sarepta Therapeutics shares fell over 42% in premarket trading on Tuesday, after its gene therapy for a progressive muscle-wasting disorder failed to meet the main goal in a trial that was key to the ...
Sarepta Therapeutics shares plunge as gene therapy trial falls short of primary goal
Sarepta Therapeutics Inc. shares SRPT, +0.77% dropped more than 40% premarket on Tuesday after the company said a trial of its gene therapy for Duchenne muscular dystrophy fell short of its main goal.
Sarepta Stock Sinks on Mixed Gene Therapy Results
In a gene therapy study for patients with Duchenne muscular dystrophy, the primary endpoint was not met.
Sarepta's gene therapy fails to meet primary goal in rare muscular dystrophy trial
Sarepta Therapeutics' gene therapy to treat Duchenne muscular dystrophy failed to reach statistical significance in a late-stage trial, the company reported after the bell on Monday.